Drug Development

Articles

A development and manufacturing partnership with Thermo will allow Civica to expand its internal pipeline of medications for use in emergency and critical care in the United States, further preventing the risk of drug shortages. 

Thermo Fisher to Partner with Civica

By halting the withdrawal process, Civica could further its goal to stabilize the supply of generic medications and prevent drug shortages in the United States. 

Civica Looks to Take on Soon-To-Be Retired or Withdrawn ANDAs

The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.

Nationwide Children’s Hospital Forms Gene Therapy Company, Andelyn Biosciences

FDA has granted fast track designation for Novavax’s NanoFlu, a recombinant quadrivalent flu vaccine, for use by adults age 65 years and older.

Novavax Granted Fast Track Designation for NanoFlu in Older Adults

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.


2020 Outlook for Biopharma Manufacturing

Generic pharmaceutical company, Hikma Pharmaceuticals, and biopharmaceutical company, Arecor, have entered into an exclusive agreement for the development and commercialization of a ready-to-use injectable medicine.


Hikma, Arecor Enter Exclusive Agreement for Ready-to-Use Medicine

Under the agreement, Almirall will leverage WuXi Biologics’ proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.

WuXi Biologics, Almirall Partner to Develop Bispecific Antibodies for Skin Diseases

The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.

Avacta, Daewoong Pharmaceutical Form Immunotherapy Joint Venture

Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.

ProBioGen Inks Commercial GlymaxX Deal with Roche

Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200. 

Formulation and Drug Delivery